Development of the clinical assessment scale in autoimmune encephalitis.

Tocilizumab treatment for new onset refractory status epilepticus.

LGI1 expression and human brain asymmetry: insights from patients with LGI1-antibody encephalitis.

Bortezomib treatment for severe refractory anti-NMDA receptor encephalitis

Botulinum toxin treatment for hypersalivation in anti-NMDA receptor encephalitis.

Anti-LGI1 encephalitis is associated with unique HLA subtypes.

Tocilizumab in Autoimmune Encephalitis Refractory to Rituximab: An Institutional Cohort Study.

Prevalence of antineuronal antibodies in patients with encephalopathy of unknown etiology: Data from a nationwide registry in Korea.

Frequent rhabdomyolysis in anti-NMDA receptor encephalitis.

Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort

Predictors of survival for patients with cancer after cryptogenic stroke.

Clinical manifestations of patients with CASPR2 antibodies.

Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis.

VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy.

miR-206 regulates brain-derived neurotrophic factor in Alzheimer disease model.

Slowed progression in models of Huntington disease by adipose stem cell transplantation.

Reduced circulating angiogenic cells in Alzheimer disease.

Anti-inflammatory mechanism of intravascular neural stem cell transplantation in haemorrhagic stroke.